-
Je něco špatně v tomto záznamu ?
Lenvatinib for the treatment of kidney cancer
H. Študentová, D. Vitásková, B. Melichar,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem, přehledy
- MeSH
- chinoliny aplikace a dávkování MeSH
- everolimus aplikace a dávkování MeSH
- fenylmočovinové sloučeniny aplikace a dávkování MeSH
- karcinom z renálních buněk farmakoterapie patologie MeSH
- lidé MeSH
- nádory ledvin farmakoterapie patologie MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky farmakologie terapeutické užití MeSH
- receptory vaskulárního endoteliálního růstového faktoru antagonisté a inhibitory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- srovnávací studie MeSH
INTRODUCTION: Sequential administration of single targeted agents has evolved as the dominant paradigm in advanced RCC treatment. Lenvatinib plus everolimus is the first combination therapy in advanced RCC to show improvement in efficacy compared to monotherapy in advanced RCC while maintaining manageable toxicity profile. Areas covered: This review gives a brief overview of the contemporary clinical data on lenvatinib including its mechanism of action, pharmacokinetics, efficacy and safety profile in combination with everolimus. The clinical applications of lenvatinib in combination with everolimus are addressed within the context of the current competitive therapeutic landscape of RCC. Expert commentary: Lenvatinib is a new VEGF receptor-targeted tyrosine kinase inhibitor approved in combination with everolimus for second-line therapy in patients with advanced renal cell carcinoma progressing on a first-line VEGF receptor-targeted tyrosine kinase inhibitor. The combination of lenvatinib with everolimus significantly improved progression-free survival compared with everolimus with a hazard ratio of 0.40 and increased objective response to 43%. Optimal sequence of therapy targeting the tumor and the immune system remains a challenge and further investigation is warranted.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012684
- 003
- CZ-PrNML
- 005
- 20190411114730.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14737140.2018.1470506 $2 doi
- 035 __
- $a (PubMed)29737893
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Študentová, Hana $u a Department of Oncology , Palacký University Medical School Teaching Hospital , Olomouc , Czech Republic.
- 245 10
- $a Lenvatinib for the treatment of kidney cancer / $c H. Študentová, D. Vitásková, B. Melichar,
- 520 9_
- $a INTRODUCTION: Sequential administration of single targeted agents has evolved as the dominant paradigm in advanced RCC treatment. Lenvatinib plus everolimus is the first combination therapy in advanced RCC to show improvement in efficacy compared to monotherapy in advanced RCC while maintaining manageable toxicity profile. Areas covered: This review gives a brief overview of the contemporary clinical data on lenvatinib including its mechanism of action, pharmacokinetics, efficacy and safety profile in combination with everolimus. The clinical applications of lenvatinib in combination with everolimus are addressed within the context of the current competitive therapeutic landscape of RCC. Expert commentary: Lenvatinib is a new VEGF receptor-targeted tyrosine kinase inhibitor approved in combination with everolimus for second-line therapy in patients with advanced renal cell carcinoma progressing on a first-line VEGF receptor-targeted tyrosine kinase inhibitor. The combination of lenvatinib with everolimus significantly improved progression-free survival compared with everolimus with a hazard ratio of 0.40 and increased objective response to 43%. Optimal sequence of therapy targeting the tumor and the immune system remains a challenge and further investigation is warranted.
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D000971
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a everolimus $x aplikace a dávkování $7 D000068338
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a fenylmočovinové sloučeniny $x aplikace a dávkování $7 D010671
- 650 _2
- $a chinoliny $x aplikace a dávkování $7 D011804
- 650 _2
- $a receptory vaskulárního endoteliálního růstového faktoru $x antagonisté a inhibitory $7 D040262
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vitásková, Denisa $u a Department of Oncology , Palacký University Medical School Teaching Hospital , Olomouc , Czech Republic.
- 700 1_
- $a Melichar, Bohuslav $u a Department of Oncology , Palacký University Medical School Teaching Hospital , Olomouc , Czech Republic. b Institute of Molecular and Translational Medicine , Palacký University Medical School Teaching Hospital , Olomouc , Czech Republic.
- 773 0_
- $w MED00174405 $t Expert review of anticancer therapy $x 1744-8328 $g Roč. 18, č. 6 (2018), s. 511-518
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29737893 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411114747 $b ABA008
- 999 __
- $a ok $b bmc $g 1391994 $s 1050989
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 18 $c 6 $d 511-518 $e 20180508 $i 1744-8328 $m Expert review of anticancer therapy $n Expert Rev Anticancer Ther $x MED00174405
- LZP __
- $a Pubmed-20190405
